tradingkey.logo

Briacell Phase 2 Survival Data Beats Leading Standard In Hr+ Breast Cancer

ReutersApr 16, 2025 11:34 AM

- Briacell Therapeutics Corp BCT.TO:

  • BRIACELL PHASE 2 SURVIVAL DATA BEATS LEADING STANDARD IN HR+ BREAST CANCER

  • BRIACELL THERAPEUTICS CORP - BRIA-IMT SHOWS 17.3 MONTHS MEDIAN OVERALL SURVIVAL IN HR+ MBC PATIENTS

  • BRIACELL THERAPEUTICS CORP - BRIA-IMT SURVIVAL DATA IN TNBC PATIENTS COMPARABLE TO TRODELVY

  • BRIACELL THERAPEUTICS CORP - NO BRIA-IMT RELATED DISCONTINUATIONS REPORTED TO DATE

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI